NCT01473381

Safety and Efficacy of Vilazodone in Major Depressive Disorder

A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,162 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Vilazodone	Vilazodone was supplied as film-coated tablets.
DRUG	Placebo to citalopram	Placebo to citalopram was supplied as a capsule.
DRUG	Placebo to vilazodone	Placebo to vilazodone was supplied as film-coated tablets.
DRUG	Citalopram	Citalopram was supplied as encapsulated tablets.

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2011-11-17
• Last updated: 2014-08-08
• Results posted: 2014-08-08

Locations

54 sites across 1 country: United States